Recruiting Clinical Trials

Displaying 211 - 220 of 242 result(s)
Study Title Condition Phase Location
A Phase 1, Single Dose, Open-label Study to Investigate the Pharmacokinetics and Safety of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function Hepatic Impairment Phase 1
  • Country: 
    United States
A Multi-center, Randomized, Placebo-controlled Patient and Investigator-blinded Study to Explore the Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy (nHCM) Cardiomyopathy, Hypertrophic Phase 2
  • Country: 
    United States
  • Country: 
    Germany
  • Country: 
    Greece
  • Country: 
A 24-month, Open-label, Prospective, Multicenter Interventional, Single-arm Study Assessing the Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Relapsing Multiple Sclerosis (RMS) Patients in China Relapsing Multiple Sclerosis (RMS) Phase 4
  • Country: 
    China
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-a ... Chronic Spontaneous Urticaria Phase 3
  • Country: 
    United States
  • Country: 
    Canada
  • Country: 
    China
  • Country: 
A Phase I/IIa Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Whole-body Distribution, Radiation Dosimetry and Anti-tumor Activity of [177Lu]-NeoB Administered in Patients With Advanced Solid Tumors Known to Overexpress Gastrin-r ... Neoplasms Phase 1, Phase 2
  • Country: 
    United States
  • Country: 
    Austria
  • Country: 
    Netherlands
A 5-year, Randomized, Double-blind, Placebo-controlled, Multi-center Study Assessing the Efficacy, Safety, and Tolerability of Intra-articular Regimens of LNA043 Versus Placebo in Patients With Symptomatic Knee Osteoarthritis Osteoarthritis Phase 2
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    China
  • Country: 
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab, to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability up to 52 Weeks in Chinese Participants With Active Non-radiographic Axia ... Non-radiographic Axial Spondyloarthritis Phase 3
  • Country: 
    China
A Multi-center, Double-blinded and Open-label Extension Study to Evaluate the Efficacy and Safety of Ligelizumab as Retreatment, Self-administered Therapy and Monotherapy in Chronic Spontaneous Urticaria Patients Who Completed Studies CQGE031C2302, C ... Chronic Spontaneous Urticaria Phase 3
  • Country: 
    United States
  • Country: 
    Argentina
  • Country: 
    Australia
  • Country: 
A Two-year, Phase III Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Evaluate the Safety, Efficacy, and Tolerability of 300 mg s.c. Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Neph ... Lupus Nephritis Phase 3
  • Country: 
    United States
  • Country: 
    Argentina
  • Country: 
    Australia
  • Country: 
A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa Hidradenitis Suppurativa Phase 3
  • Country: 
    United States
  • Country: 
    Argentina
  • Country: 
    Australia
  • Country: